**CName of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 22624**

**Manuscript Type:** **REVIEW**

**Cytomegalovirus and ulcerative colitis: Place of antiviral therapy**

Sylvie Pillet, Bruno Pozzetto, Xavier Roblin

Pillet S *et al.* Antiviral therapy and ulcerative colitis

**Sylvie Pillet, Bruno Pozzetto, Xavier Roblin,** Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP)-EA3064, Faculty of Medicine of Saint-Etienne, University of Lyon, 69365 Lyon Cedex 7, France

**Sylvie Pillet, Bruno Pozzetto,** Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, 42025 Saint-Etienne Cedex 2, France

**Xavier Roblin,** Department of Gastroenterology, University Hospital of Saint-Etienne, 42025 Saint-Etienne Cedex 2, France

**Author** **contributions**:Pillet S, Pozzetto B and Roblin X both contributed to perform the previous studies related to this review, to review in-depth the available literature, to write the manuscript and to approve all the successive versions, including the last one.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Xavier Roblin, Professor, MD, PhD,** Department of Gastroenterology, University Hospital of Saint-Etienne, 42055 Saint-Etienne Cedex 2, France.xavier.roblin@chu-st-etienne.fr

**Telephone: +**33-4-7828985

**Fax:** +33-4-77828452

**Received:** September 9, 2015

**Peer-review started:** September 10, 2015

**First decision:** October 14, 2015

**Revised:** November 19, 2015

**Accepted:** December 19, 2015

**Article in press:**

**Published online:**

**Abstract**

The link between cytomegalovirus (CMV) infection and inflammatory bowel diseases remains an important subject of debate. CMV infection is frequent in ulcerative colitis and has been shown to be potentially harmful. The diagnosis of CMV reactivation needs to be performed using relevant tools, that include an *in situ* detection of viral markers either by immunohistochemistry or by nucleic acid amplification techniques; determination of the density of infection by using quantitative tools (the number of infected cells or the number of copies of the genome) is particularly important. Although CMV reactivation can be considered as an innocent bystander in active flare-ups of refractory ulcerative colitis (UC), more and more studies suggest a deleterious role of CMV in this situation. Indeed, the presence of colonic CMV infection has been suggested to be a factor linked to a decreased response to steroids and other immunosuppressive therapies. Reciprocally, some treatments and notably steroids and cyclosporine A were shown to favor CMV reactivation, which seems not to be the case for therapies using anti-tumor necrosis factor drugs. According to these findings, in flare-ups of refractory UC, it is now recommended to look for the presence of CMV reactivation by using quantitative tools in colonic biopsies and to treat them with ganciclovir in cases of high viral load or severe disease.

**Key words:** Human cytomegalovirus; Ulcerative colitis; Inflammatory bowel disease; Ganciclovir; Viral load; flare-up; Inflammation; Intestinal mucosa; Quantitative polymerase chain reaction

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is increasing evidence for the deleterious effect of *in situ* cytomegalovirus (CMV) reactivation in flare-ups of refractory ulcerative colitis. In patients older than 30 years with a high density of infection in the colonic tissue or with stigmata of severe disease associated with colonic markers of CMV reactivation (whatever the density of infection), treatment with ganciclovir is highly recommended together with anti- tumor necrosis factor Mab therapy in the absence of any contraindication of these drugs. For validating the present strategy based on our experience and the in-depth analysis of the available literature presented in this review, prospective randomized controlled studies are urgently needed.

Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: Place of antiviral therapy. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Cytomegalovirus (CMV) belongs to the *Herpesviridae* family. The viral genome consists of linear double-stranded DNA protected by a capsid and an envelope. After primary infection, which may or may not be symptomatic, the virus is known to maintain a persistent, life-long infection of the host, often as a latent form that can be found in several cell types. These cells are mainly myeloid progenitors, monocytes and endothelial cells, meaning that CMV could be latent in several organs or tissues, and especially in the colon[1,2]. During the latent stage, the CMV genome is present as an episomal circular form in the cell nucleus with minimal viral expression and without viral particle production. CMV can reactivate from the latent stage, leading to the production of new viral particles. CMV reactivation is triggered by inflammation or immunosuppression. Beside reactivation from an endogenous latent virus, re-infection can be induced by an exogenous strain present in a tissue/organ graft or blood transfusion.

The host immune response is critical in controlling CMV infection. Cellular immunity, especially natural killer (NK) cells, and interferons (IFNs) play a major role both at the stage of primary infection and in long-term control of the infection. Consequently, the clinical expression of CMV infection is generally absent in an immunocompetent host, even if some severe infections, especially colitis[1–5], have been reported in the literature. In contrast, the most preoccupant manifestations of CMV infection are observed in immunocompromised patients with altered cellular immunity, *i.e.,* after transplantation of solid organ grafts or hematopoietic stem cells, in cases of HIV infection, in patients undergoing chemotherapy or immunotherapy, and during pregnancy. Clinical manifestations may vary from acute febrile illness to organ disease (retinitis, pneumonitis, encephalitis, colitis, hepatitis, *etc*.)[6].

CMV infection is of particular interest in inflammatory bowel diseases (IBD) that combine inflammation in the colon and the long term maintenance of immunosuppressive therapies, both being able to reactivate latent CMV[7]. Local inflammation in the bowel wall leads to the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α). As a consequence, these cytokines are able to activate CMV replication and the migration of CMV-infected monocytes and macrophages in the inflamed tissue to further propagate infection, generating a vicious cycle of pathology[2]. However, IBD is a complex entity that involves different clinical situations dominated by Crohn disease (CD) and ulcerative colitis (UC). In CD, severe CMV primary infections have been reported, some of them being complicated further by hemophagocytic lymphohistiocytosis[8]. The administration of ganciclovir was shown to contribute to clinical remission[9]. However, and although the seroprevalence to CMV is similar in CD and UC patients[10], CMV reactivation was shown to be much less frequent in CD than in UC patients, with no significant impact on clinical evolution[10–20]. This observation can be attributed to the different cytokine profiles observed in these two IBDs: CD is most likely attributed to Th1 and Th17 CD4+ T-cell differentiation with secretion of interferon γ that exerts an inhibiting effect on CMV replication; in contrast, UC exhibits a Th2 profile with limited secretion of antiviral cytokines, which could favor viral reactivation or tolerance[21]. Consequently, CD will be excluded from the scope of this review.

The use of various virological methods for diagnosing CMV reactivation impacts the results obtained when exploring the role of this agent in UC and has led to controversial theories. Once the role of CMV is established in the evolution of UC, several predictive factors can be selected in order to identify those patients who are more likely at risk to develop CMV reactivation in the colon and that may therefore benefit from antiviral therapy. Accordingly, the aim of this review is to answer four successive questions: (1) how to accurately diagnose CMV reactivation in colonic tissue of UC patients;(2) what is the impact of colonic CMV infection in the evolution of UC; (3) what are the predictive factors that may help to identify those patients at risk of unfavorable evolution; and (4) in this population, can antiviral therapy be of any use in improving the long-term evolution of UC?

**HOW TO ACCURATELY DIAGNOSE CMV REACTIVATION IN COLONIC TISSUE OF UC PATIENTS?**

Figure 1 recapitulates the different techniques that are presently used for the diagnosis of CMV infection. As shown in this Figure, only a few techniques are indicated for the current diagnosis of CMV reactivation in the colonic tissue of UC patients.

Firstly, specific IgG serology, usually performed by enzyme-linked immunosorbent assay (ELISA), is necessary to identify those patients who have already been in contact with CMV and consequently could be at risk of an endogenous reactivation at the colonic level. In seropositive patients, two kinds of techniques were shown to be able to identify CMV reactivation at this level.

The first group of techniques relies on histological examination of colonic tissue. The direct examination of colon biopsies after hematoxylin and eosin (HE) staining can show typical aspects of “owl’s eye” images (Figure 1) but this technique is poorly sensitive and frequently leads to false-negative results. Immunohistochemistry (IHC) on colonic tissue is much more sensitive and can be quantitative by numbering the infected cells[22–25]. However, a recent paper from McCurdy *et al*[26] indicated that a great number of biopsy samples must be examined in order to achieve adequate sensitivity.

The second group of techniques is based on the detection of CMV DNA in colonic tissue. *In situ* hybridization can be used for this purpose but, as for HE staining, this technique lacks sensitivity and can only identify severe CMV reactivation episodes. It has largely been replaced by molecular techniques based on nucleic acid amplification tests (NAATs). Although very sensitive, qualitative PCR with two rounds of amplification (nested PCR) should be avoided because of the risk of cross-contamination and false-positive results[27,28]. In contrast, real-time quantitative PCR (qPCR) assays are very sensitive, allowing the detection of low-level reactivation, permit an accurate determination of the viral load, and can be automated. In contrast with IHC, they give no information on the infectious potential of the detected genome, nor on the stage (latent or productive) of CMV infection. To optimize the predictive value of these tests, it is necessary to determine the thresholds of CMV DNA load that would require initiating antiviral therapy[6,29]. One of the main difficulties with NAATs is the inter-laboratory standardization of quantitative data[6,30,31], together with the harmonization of viral load expression in tissue specimens (copies[10,25,29,32–34] or international units[6], per mg of tissue[10,25], µg of DNA[14,34] or number of cells[29,32,33]). This lack of standardization makes the comparison of results between studies difficult and universally-accepted cut-off values of CMV DNA load for assessing CMV disease have still to be defined[24,32,33]. Another important feature with NAATs is the risk of a false-negative result if the biopsy is performed at distance from an inflamed focus; indeed, CMV markers are detected in inflamed tissue only[10,14,25,34] and inflammation[35–40] is present in the mucosa as foci that are sometimes difficult to identify during colonoscopy. To minimize this risk, it is our experience to measure CMV DNA on a couple of biopsies taken at the same time and to use the result exhibiting the highest viral load (manuscript submitted). As detailed below, the presence of ulcers is correlated with that of viral stigmata[20,25,41,42], which indicates that these areas must be privileged in performing the biopsies. As an alternative to colonic biopsies, some authors have proposed the determination of viral load in feces[43–45]; however, this technique was recently shown to be poorly sensitive for the detection of CMV colitis in immunosuppressed patients[46].

IHC is still considered as the gold standard for the identification of CMV in tissue sections[26,47,48]. However, the choice between IHC and NAAT (mainly qPCR) for detecting CMV reactivation in colon biopsy of UC patients is a matter of ongoing debate[25], even in current international recommendations[49], although an increasing number of laboratories are switching from histology-based techniques to qPCR assays for the quantification of CMV load in colonic tissue, due to the simplicity and rapidity of the latter tests. Indeed, with current NAATs the results of viral load can be recovered within one working day. Due to the absence of any indication on the infectivity of a detected genome, the use of viral load thresholds would avoid the useless treatment of latent infection.

**WHAT IS THE IMPACT OF COLONIC CMV INFECTION ON THE EVOLUTION OF UC?**

***General considerations***

The implication of CMV reactivation in colonic tissue on the clinical evolution of UC has been highly debated[22,27,50]. Table 1[10,12-17,20,22,41,42,51-85] lists, in chronological order, the main studies that have tried to explore this relationship. Some of them have reported CMV markers in patients without an impact on IBD evolution, which has led to the idea that CMV infection could be considered as an “innocent bystander”[27] or by-product of the pathology. Many others have shown a negative impact of CMV infection in UC evolution and, in some of them, an improvement of clinical status when an antiviral therapy was initiated, suggesting an active role of CMV.

In our opinion, many of these discrepancies are related to misleading definitions of the populations of patients included in the studies or to the use of inadequate tools for the evaluation CMV reactivation in the gut: (1) patients with CMV primary infection exhibiting CMV colitis were sometimes mixed with patients with CMV reactivation, notably in ancient studies, which introduces a bias in the evaluation of prognosis[53,58,86–90]; (2) several studies, including some recent ones[41,74,78,84], have evaluated CMV markers in both UC and CD patients, although these two IBD are very different in terms of the risks of CMV reactivation, as discussed above; (3) a few studies used peripheral blood markers, and notably pp65 antigenemia (see Figure 1), to evaluate CMV reactivation in UC patients; positive antigenemia was associated with steroid refractoriness and UC exacerbation in one study[71], to corticoresistance in another[5] and to the presence of ulcer and risk of colectomy in a third[76]; however, viremia is poorly sensitive[10,14,19,64,77,78,82], no threshold has been established for starting therapy and the search for CMV should be performed in colonic biopsy in order to evaluate the risk of reactivation at an early stage of infection corresponding to an increased chance of successful antiviral treatment; and (4) finally, and as stated in the previous section, the comparison of clinical results between studies is rendered difficult by the diversity of techniques that are used to determine CMV reactivation at the colonic level (IHC *vs* NAATs) and the lack of standardization of the different tests used for quantifying the viral load.

Despite these discrepancies, there is an increasing consensus for considering CMV reactivation as a marker of poor prognosis in UC patients, as illustrated by the results of the studies listed in Table 1 and by the recommendations of international guidelines[47,49,91] for the systematic detection of CMV reactivation in flare-ups of UC patients and in using antiviral drugs in particular circumstances that will be detailed later in this review.

***Factors implicated in the occurrence of CMV reactivation in UC patients***

**Role of immune therapies:** Administration of steroids is a known predisposing factor for CMV reactivation by suppressing anti-CMV T cell specific function[92] and by directly activating viral replication[93,94]. Indeed, many studies have documented this risk in UC patients[14,17,32,52,59,80]. It has been shown that administration of steroids over a period of at least 3 mo at a dose of at least 10 mg is associated with a risk of CMV reactivation, without effect of cumulative doses[52]. The prevalence of CMV reactivation increased with the exposition of high-dose steroid therapy for 7 to 14 d[17].

With regards to immuno-modulatory therapies other than steroids, cyclosporine (CyA) therapy is also associated with the risk of active CMV infection[62,64,83]. In a study including 23 patients with severe UC under CyA treatment, 18 of them developed a CMV infection as illustrated by the presence of IgM antibody, CMV DNA or inclusion bodies by histology after approximately 8 d of treatment[62]. In a prospective study, CMV infection was observed in 5 out of 6 UC patients after 7–10 d of CyA treatment[64]. Consequently, the risk of CMV infection should be carefully monitored when this drug is used as an alternative to other contraindicated immuno-modulatory therapies. In contrast, the use of azathioprine or anti-TNF monoclonal antibodies (Mabs) was not shown to be associated to an increased risk of CMV reactivation[10,41,52,64,95–99]. We recently reported 109 consecutive flares-up of UC in patients under anti-TNF maintenance therapy; these patients were not shown to be at a higher risk of CMV reactivation and, reciprocally, the occurrence of CMV reactivation had no consequence on the further evolution of UC. These results plead for the preferential use of these molecules in cases of refractory flare-up associated with CMV reactivation[100]. However, in a recent study combining CD and UC patients, the use of immuno-modulators including thiopurines or methotrexate was significantly associated with occurrences of CMV disease[41]. Tacrolimus was recently proposed as an alternative to previous treatments, especially in cases of refractory flare-up[85,98]; further studies are needed to appreciate the risk of developing CMV reactivation in this context[101].

**Age > 30 yr:** Two very recent studies have documented the risk of CMV reactivation in IBD patients older than 30 years. In a retrospective case-control study performed on 68 IBD patients (66% with UC) exhibiting CMV infection by tissue analysis who were each matched to three controls without stigmata of CMV infection, McCurdy *et al*[41] showed that CMV disease was significantly associated with an age older than 30 years; no stratification was performed by type of IBD (CD or UC). In another retrospective study, Gauss *et al*[84] recorded positive CMV markers in 21 IBD patients - 18 with CMV DNA in colonic biopsy and 3 with positive blood antigenemia (the PCR assay was not done)- out of a total of 100 patients, most of them (17/21) exhibiting UC. The presence of CMV markers was significantly associated with age ≥ 30 years (OR: 14.26; 95%CI: 2.89-118.57). Despite the high significance of these data, they rely only on two studies with a low number of patients, which implies that further trials are required to consolidate these observations.

**Other predictive factors of CMV infection in IBD patients:**The two retrospective studies mentioned in the above paragraph also documented other predictive factors of CMV infection in IBD patients. In addition to age > 30 years, McCurdy *et al*[41] identified four additional factors of risk: medically refractory IBD, the presence of ulcers at endoscopy, treatment with corticosteroids and treatment with immuno-modulators (with the exception of anti-TNF Mab). After adjustment in a multivariate model, refractory disease, treatment with immuno-modulators and age > 30 years remained independently associated with CMV infection. The authors propose a CMV risk score based on these criteria for the prediction of CMV infection in IBD patients. Furthermore, in addition to age > 30 years, the case-control study of Gauss *et al*[84] identified a blood leukocyte count < 11000/mL, disease duration at admission < 60 mo and the presence of immunosuppressive therapy at admission as significant predictors of CMV infection in IBD patients. As no stratification was done by type of IBD in these two retrospective studies, it would be interesting to specifically reevaluate these predictors in UC patients who are most at risk of CMV infection amongst IBD subjects.

**WHAT ARE THE PREDICTIVE FACTORS OF UNFAVORABLE EVOLUTION IN UC PATIENTS WITH CMV INFECTION?**

***Resistance to steroids and to other immunosuppressive therapies***

CMV reactivation was recorded as one of the most important risk factors for steroid-refractory UC. A retrospective study that investigated CMV infection by IHC in 77 surgical specimens reported a rate of CMV infection of 27.3% in samples from steroid-refractory UC patients compared to 9.1% in those from steroid-sensitive ones[102]. In the prospective study that we conducted on 42 consecutive patients hospitalized for moderate to severe UC and treated with IV steroids, the only factor associated by multivariate analysis with CMV DNA in inflammatory tissue was the resistance to steroids (OR: 4.7; 95%CI: 1.2-22.5)[10]. Two other prospective studies had reported the same association between resistance to steroids and CMV reactivation[52,64]. Recent studies[71,78] including 2 multivariate analyses[41,84] confirmed the link between CMV reactivation and steroid resistance. In a meta-analysis published this year and summarizing 11 studies involving 867 IBD patients, the relative risk for steroid resistance was significantly higher in CMV positive patients (OR: 2.07; 95%CI: 1.80-2.39)[103].

As shown in our work for flare-ups of refractory UC, CMV reactivation impacts the response to immunosuppressive therapies, including anti-TNF Mabs[10]. In a similar context, Yamada *et al*[81] showed that the induction remission rate by infliximab was lower (54.5%) in CMV-positive patients than in CMV negative ones (81.8%) although the difference was not statistically significant.

***Acute severe colitis and requirement of colectomy***

Since the first description of CMV markers in surgical specimens[104], a higher rate of colectomy have been observed in cases of CMV reactivation *vs* CMV negative groups[20,69,76,85]. In the prospective study published by Domenech *et al*[64], colectomy was performed in 3/6 patients exhibiting CMV reactivation compared to 2/12 patients without markers of CMV infection. The prevalence of CMV markers detected using IHC in surgical specimens was also shown to be higher in severe UC than in refractory ones (25% *vs* 8.3% and 25% *vs* 2.5% in[60] and[56], respectively). In a recent report, Yoshino *et al*[69] showed that the colectomy-free time was higher in patients without CMV colitis. Finally, Matsumoto and Yoshida reported recently that CMV infection and steroid use were independent risk factors for hospitalization because of UC aggravation and need for surgery[79]. By retrospective analysis of a surgery database including 1100 patients, Uchino *et al*[105] recorded 7 cases exhibiting UC-related lesions in the stomach and small intestine after colectomy; 6 of 7 exhibited CMV infection either with positive antigenemia or CMV markers in tissue (IHC or PCR). These severe CMV infections were all refractory to ganciclovir treatment.

***The presence of ulcers with endoscopic examination***

Several studies argue for a link between the presence of ulcers after endoscopic examination, CMV reactivation and unfavorable evolution. In a paper dealing with UC hospitalized patients due to exacerbation of symptoms, colonoscopic findings were compared between 15 CMV-positive patients and 58 CMV-negative patients, as determined by blood antigenemia: more abnormalities (irregular ulceration, wide mucosal defect) were observed in patients with UC complicated by CMV infection[66]. More recently, the retrospective study mentioned previously[41] reported a trend towards severe endoscopic disease in CMV-infected IBD patients (OR: 1.67; 95%CI: 0.85-3.32); in the subgroup of UC patients, the presence of endoscopic ulcers was significantly associated with CMV disease (OR: 3.00; 95%CI: 1.38-6.51). In another study, the absence of large ulcers was predictive of non-active CMV infection in UC patients positive for the presence of colonic CMV DNA: the 10 patients exhibiting this profile attained remission without antiviral therapy at 2 mo and maintained remission[42]. However, other studies, including ours[10,54], did not identify stigmata of tissue injury as a marker of CMV infection; it may depend upon the severity of UC in the studied populations that may have been lower in the latter studies.

***Density of viral infection***

Using either molecular or histological assays to evaluate the density of viral infection, this quantitative or semi-quantitative marker was shown to be related to the severity of colonic lesions in UC patients. Using histopathology, Nguyen *et al*[22] distinguished low-grade CMV infection (when IHC was positive only) from high grade infection (detected by HE staining): colectomy rates were respectively of 29% and 83% in untreated patients. In a recent paper, Jones *et al*[83] defined high-grade CMV density by the presence of more than 4 typical inclusions in biopsy specimens. Similarly, Kuwabara *et al*[13] proposed that dense CMV disease, defined as more than 10 inclusions per histologic section, was shown to be predictive of significantly higher final daily doses of steroids before surgery, and showed increased steroid resistance; in addition, the frequency of emergency surgery was higher and postoperative hospital stay was significantly longer in the dense CMV group.

By using quantitative PCR in colon biopsies, we performed a random sensitivity analysis for correlating the presence of CMV in tissue with the occurrence of resistance to the successive lines of treatment[10]. A positive colonic CMV load was associated with an increased risk of steroid resistance [likelihood ratio (LR +) of 3.0], with a sensitivity of 50% and a specificity of 100% (AUROC = 0.54; *P* < 0.05). A viral load of > 250 copies/mg of tissue was predictive of a resistance to three successive lines of treatment with a sensitivity of 100% and a specificity of 66.6% (LR + of 4.33; AUROC = 0.85; *P* < 0.05). In contrast, the absence of CMV DNA in tissue was predictive of a favorable response to any treatment with a sensitivity of 100% and a specificity of 50% (LR + of 2.21; AUROC = 0.65; *P* < 0.05).

**WHAT IS THE BENEFIT OF ANTI-CMV THERAPY ON THE EVOLUTION OF UC IN PATIENTS WITH CMV REACTIVATION?**

***Systematic review of literature-available data***

Regarding the management of CMV infection in UC patients, the guidelines of the European Crohn’s and Colitis Organization in 2014 are as follows: “Screening for CMV infection is not necessary before starting immunomodulator therapy. In patients with acute steroid-resistant colitis, CMV should be excluded, preferably by tissue PCR or immunohistochemistry, before increasing immunomodulator therapy. In case of severe steroid-resistant colitis with CMV detected in the mucosa during immunomodulator therapy, antiviral therapy should be initiated and discontinuation of immunomodulators considered until colitis symptoms improve. In case of systemic CMV disease, immunomodulator therapy must be discontinued”[49]. However, randomized controlled trials would be useful in reinforcing the level of evidence supporting these guidelines.

If most of the Gastroenterology Societies recommend antiviral treatment of severe flare-ups of UC exhibiting CMV markers in inflamed tissue, no recommendations are given on which antiviral drug should be used and for what duration. No study has compared ganciclovir and foscanet in this indication and no data are available on the pharmacokinetics of antiviral drugs in colonic tissue, notably regarding the difference between ganciclovir and valganciclovir and the role of possible malabsorption in inflamed tissue. In contrast to transplant recipients[106], the overall incidence of CMV resistance to ganciclovir in IBD has never been analyzed. In this context, most authors use ganciclovir to treat CMV reactivation in UC patients (reviewed in Shukla *et al*[48]). In our clinical practice, we use empirically IV ganciclovir for one week followed by oral valganciclovir for two more weeks but the relevance of this strategy has not been evaluated.

A lot of case reports, as well as punctual prospective studies, have reported a clinical improvement associated with a reduction of colectomy rate when UC patients with CMV reactivation received ganciclovir (or exceptionally, foscarnet). In a previous review paper[50], we collected 7 prospective studies[14,34,51,64,67,68,95] that analyzed the efficacy of treatment of CMV reactivation by ganciclovir in UC patients: from a total of 58 treated patients, 46 presented a clinical improvement and 11 justified colectomy (18%).

Several studies analyzed the benefit of ganciclovir on colectomy rate according to the density of CMV infection. In the study of Nguyen *et al*[22], the antiviral treatment did not change colectomy rate for the patients with low grade CMV infection (31% *vs* 29% without CMV treatment) but it significantly decreased the colectomy rate for those with high grade CMV infection (44% *vs* 83% without CMV treatment). Similarly, Jones *et al*[83] argued that antiviral treatment significantly reduced the risk of surgery (OR: 0.31; 95%CI: 0.14-0.70); patients with high grade infection showed a significant benefit to antiviral therapy whereas those with low grade infection presented higher rates of colectomy. In the study performed in our hospital[10], 8 patients with a high CMV DNA load in colon and who had failed to respond to at least two lines of treatment, were treated with ganciclovir for 15 d in addition to their ongoing immunosuppressive therapy; for 7 of them, a clinical remission was obtained with a sustained response to the last therapeutic line after a follow-up of 6 mo, which resulted in a step-down therapeutic strategy for all of them[10].

Recently, a meta-analysis was performed to determine the impact of antiviral therapy on the colectomy rate in UC patients presenting CMV infection[48]. Fifteen studies were included in this meta-analysis for a total of 333 patients; 43.2% were treated with antiviral therapy and 56.8% were not. The diagnosis was made primarily by HE and/or IHC in 7 studies and by tissue PCR in 4 studies. Globally, no difference was noticed in terms of colectomy between patients treated with antiviral therapy and those without treatment (OR: 0.92; 95%CI: 0.31–2.76) with a moderate heterogeneity (*I*2 = 65%). There was no significant difference in the risk of colectomy based on the method of CMV diagnosis. Next, the authors analyzed the risk of colectomy in those patients with corticosteroid (CS)-refractory UC related to CMV reactivation; 8 studies were available concerning 139 patients, 77 of them having received an antiviral therapy. The risk of colectomy was significantly lower in patients with CS-refractory UC treated with antiviral therapy than in patients not treated with antiviral therapy (OR: 0.20; 95%CI: 0.08–0.49) with no heterogeneity *(I*2 = 0). When the analysis was limited to studies that defined refractory disease as failure to respond to 1 week of intravenous corticosteroids, the benefit of antiviral therapy remained significant (OR: 0.23; 95%CI: 0.06–0.82). Finally, when the analysis was further stratified on the method of CMV diagnosis, the risk of colectomy remained significantly lower only when CMV infection was based on histological criteria (3 studies; OR: 0.06; 95%CI: 0.01–0.34) but not on tissue PCR (4 studies; OR: 0.31; 95%CI: 0.09–1.11). The latter observation may be related to the fact that the analysis was not adequately powered and that 3 of the 4 studies based on tissue PCR reported only qualitative results.

***Place of*** ***granulocyte/monocyte adsorptive apheresis in the treatment of CMV-related flare-ups of UC***

Granulocyte/monocyte adsorptive apheresis (GMAA) is a biological therapy consisting in the removal of the granulocytes/macrophages producing inflammatory cytokines. This strategy was evaluated in a randomized, double-blind, sham-controlled study for the treatment of UC flare-ups. The treatment was well tolerated but did not demonstrate efficacy for induction of clinical remission or response in patients with moderate-to-severe flare-ups[107]. More recently, Japanese studies have investigated the efficacy of GMAA in active UC flare-ups associated or not to colonic CMV reactivation. In a retrospective study, 11 UC patients in clinical failure under steroid and immunomodulatory therapy were treated with additional GMAA: 9 achieved remission and 2 underwent colectomy[108]. Fukuchi *et al*[70] tested this strategy in 51 active UC flare-up episodes, associated for 15 of them to *in situ* CMV infection; in the absence of steroid treatment, the clinical remission rate did not differ between UC patients, whether positive and negative for CMV (73.3% *vs* 69.4%); CMV DNA became negative in all UC patients positive for CMV who achieved clinical remission 1 week after completion of intensive GMAA but no data on long-term evolution was reported. Presently GMAA is not recommended in the treatment of UC flare-ups by American and European guidelines. Additional studies are needed to evaluate its benefit in UC patients with flare-ups associated to CMV reactivation.

***Discussion of therapeutic algorithms***

At least three therapeutic algorithms have been proposed for the intake of refractory flare-ups of UC according to the presence or not of CMV reactivation in the gut[48,50,109]. These algorithms are all relatively similar on similar lines but do not take into consideration the risk factors listed above together with the density of CMV infection[83] and the absence of reciprocal deleterious effects between anti-TNF Mabs and CMV reactivation[100]. The therapeutic algorithm that we propose in Figure 2 integrates these relatively new concepts. Of note, as recommended by the European guidelines[49], the antiviral therapy must be initiated after discontinuation of immunomodulators that will be reintroduced at the end of the flare-up.

**CONCLUSION**

Despite conflicting results, there is increasing evidence, notably in recent studies, for the deleterious effect of *in situ* CMV reactivation in flare-ups of refractory UC. In patients older than 30 years with a high density of infection in the colonic tissue or with stigmata of severe disease associated with colonic markers of CMV reactivation (whatever the density of infection), a treatment with ganciclovir appears to be highly recommendable together with anti-TNF Mab therapy in the absence of explicit contraindication of these drugs. In order to validate the present strategy based on our experience and the in-depth analysis of the available literature presented in this review, prospective randomized controlled studies are urgently needed.

**ACKNOWLEDGEMENTS**

The authors acknowledge Philip Lawrence for his careful revision of the English style of the manuscript. They are indebted to the five reviewers for their constructive remarks that helped to improve considerably the quality of the manuscript.

**REFERENCES**

1 **You DM**, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract. *Curr Gastroenterol Rep* 2012; **14**: 334-342 [PMID: 22588614 DOI: 10.1007/s11894-012-0266-4]

2 **Goodman AL**, Murray CD, Watkins J, Griffiths PD, Webster DP. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. *Eur J Clin Microbiol Infect Dis* 2015; **34**: 13-18 [PMID: 25097085 DOI: 10.1007/s10096-014-2212-x]

3 **Galiatsatos P**, Shrier I, Lamoureux E, Szilagyi A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. *Dig Dis Sci* 2005; **50**: 609-616 [PMID: 15844689]

4 **Seo TH**, Kim JH, Ko SY, Hong SN, Lee SY, Sung IK, Park HS, Shim CS, Han HS. Cytomegalovirus colitis in immunocompetent patients: a clinical and endoscopic study. *Hepatogastroenterology* 2012; **59**: 2137-2141 [PMID: 23435132 DOI: 10.5754/hge10825]

5 **Ko JH**, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, Kang CI, Chung DR, Kim YH, Lee NY, Kim KM, Song JH. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. *Clin Infect Dis* 2015; **60**: e20-e26 [PMID: 25452594 DOI: 10.1093/cid/ciu969]

6 **Pillet S**, Roblin X, Cornillon J, Mariat C, Pozzetto B. Quantification of cytomegalovirus viral load. *Expert Rev Anti Infect Ther* 2014; **12**: 193-210 [PMID: 24341395 DOI: 10.1586/14787210.2014.870887]

7 **Kandiel A**, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. *Am J Gastroenterol* 2006; **101**: 2857-2865 [PMID: 17026558 DOI: 10.1111/j.1572-0241.2006.00869.x]

8 **N'Guyen Y**, Baumard S, Salmon JH, Lemoine L, Lévêque N, Servettaz A, Jaussaud R, Strady C, Andreoletti L. Cytomegalovirus associated hemophagocytic lymphohistiocytosis in patients suffering from Crohn's disease treated by azathioprine: a series of four cases. *Inflamm Bowel Dis* 2011; **17**: E116-E118 [PMID: 21710533 DOI: 10.1002/ibd.21770]

9 **Subramanian V**, Finlayson C, Harrison T, Rice P, Pollok R. Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. *J Crohns Colitis* 2010; **4**: 199-202 [PMID: 21122506 DOI: 10.1016/j.crohns.2009.11.004]

10 **Roblin X**, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, Chambonnière ML, Garraud O, Peyrin-Biroulet L, Pozzetto B. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. *Am J Gastroenterol* 2011; **106**: 2001-2008 [PMID: 21788989 DOI: 10.1038/ajg.2011.202]

11 **Roblin X**, Pillet S, Berthelot P, Del Tedesco E, Phelip JM, Chambonnière ML, Peyrin-Biroulet L, Pozzetto B. Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. *Inflamm Bowel Dis* 2012; **18**: E1396-E1397 [PMID: 22231740 DOI: 10.1002/ibd.21907]

12 **Dimitroulia E**, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2006; **12**: 879-884 [PMID: 16954807 DOI: 10.1097/01.mib.0000231576.11678.57]

13 **Kuwabara A**, Okamoto H, Suda T, Ajioka Y, Hatakeyama K. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. *J Gastroenterol* 2007; **42**: 823-829 [PMID: 17940835 DOI: 10.1007/s00535-007-2103-3]

14 **Yoshino T**, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. *Inflamm Bowel Dis* 2007; **13**: 1516-1521 [PMID: 17828781 DOI: 10.1002/ibd.20253]

15 **Nakase H**, Yoshino T, Honzawa Y, Chiba T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. *Dig Dis Sci* 2010; **55**: 1498-1499 [PMID: 20198427 DOI: 10.1007/s10620-010-1162-0]

16 **Lévêque N**, Brixi-Benmansour H, Reig T, Renois F, Talmud D, Brodard V, Coste JF, De Champs C, Andréoletti L, Diebold MD. Low frequency of cytomegalovirus infection during exacerbations of inflammatory bowel diseases. *J Med Virol* 2010; **82**: 1694-1700 [PMID: 20827767 DOI: 10.1002/jmv.21877]

17 **Kim JJ**, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. *Dig Dis Sci* 2010; **55**: 1059-1065 [PMID: 20112061 DOI: 10.1007/s10620-010-1126-4]

18 **Aarnio MT**, Böhm JP, Nuorva KP, Pitkänen RI, Kuopio TH, Voutilainen ME. Absence of cytomegalovirus from the gastrointestinal tract of patients with active Crohn's disease. *In Vivo* 2012; **26**: 151-155 [PMID: 22210731]

19 **Antonelli E**, Baldoni M, Giovenali P, Villanacci V, Essatari M, Bassotti G. Intestinal superinfections in patients with inflammatory bowel diseases. *J Crohns Colitis* 2012; **6**: 154-159 [PMID: 22325169 DOI: 10.1016/j.crohns.2011.07.012]

20 **Al-Zafiri R**, Gologan A, Galiatsatos P, Szilagyi A. Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital. *Gastroenterol Hepatol (N Y)* 2012; **8**: 230-239 [PMID: 22723754]

21 **Strober W**, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1756-1767 [PMID: 21530742 DOI: 10.1053/j.gastro.2011.02.016]

22 **Nguyen M**, Bradford K, Zhang X, Shih DQ. Cytomegalovirus Reactivation in Ulcerative Colitis Patients. *Ulcers* 2011; **2011**: pii: 282507 [PMID: 21731826 DOI: 10.1155/2011/282507]

23 **Mills AM**, Guo FP, Copland AP, Pai RK, Pinsky BA. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. *Am J Surg Pathol* 2013; **37**: 995-1000 [PMID: 23648457 DOI: 10.1097/PAS.0b013e31827fcc33]

24 **Langner C**, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R, Geboes K. The histopathological approach to inflammatory bowel disease: a practice guide. *Virchows Arch* 2014; **464**: 511-527 [PMID: 24487791 DOI: 10.1007/s00428-014-1543-4]

25 **Zidar N**, Ferkolj I, Tepeš K, Štabuc B, Kojc N, Uršič T, Petrovec M. Diagnosing cytomegalovirus in patients with inflammatory bowel disease--by immunohistochemistry or polymerase chain reaction? *Virchows Arch* 2015; **466**: 533-539 [PMID: 25701481 DOI: 10.1007/s00428-015-1741-8]

26 **McCurdy JD**, Enders FT, Jones A, Killian JM, Loftus EV, Bruining DH, Smyrk TC. Detection of Cytomegalovirus in Patients with Inflammatory Bowel Disease: Where to Biopsy and How Many Biopsies? *Inflamm Bowel Dis* 2015; **21**: 2833-2838 [PMID: 26273816 DOI: 10.1097/MIB.0000000000000556]

27 **Lawlor G**, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? *Inflamm Bowel Dis* 2010; **16**: 1620-1627 [PMID: 20232408 DOI: 10.1002/ibd.21275]

28 **Nakase H**, Yoshino T, Matumura K, Honzawa Y, Yamamoto S, Matsuura M, Chiba T. Positive finding of colonic polymerase chain reaction for cytomegalovirus DNA is not false positive but a warning for treating patients with ulcerative colitis refractory to immunosuppressive therapies. *Inflamm Bowel Dis* 2011; **17**: E13-E14 [PMID: 20629104 DOI: 10.1002/ibd.21401]

29 **Ganzenmueller T**, Henke-Gendo C, Schlué J, Wedemeyer J, Huebner S, Heim A. Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. *J Clin Virol* 2009; **46**: 254-258 [PMID: 19748823 DOI: 10.1016/j.jcv.2009.08.008]

30 **Pang XL**, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. *Am J Transplant* 2009; **9**: 258-268 [PMID: 19178413 DOI: 10.1111/j.1600-6143.2008.02513.x]

31 **Waggoner JJ**, Pinsky BA. Comparison of automated nucleic acid extraction methods for the detection of cytomegalovirus DNA in fluids and tissues. *PeerJ* 2014; **2**: e334 [PMID: 24765569 DOI: 10.7717/peerj.334]

32 **Ciccocioppo R**, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. *World J Gastroenterol* 2015; **21**: 1915-1926 [PMID: 25684960 DOI: 10.3748/wjg.v21.i6.1915]

33 **Ciccocioppo R**. Letter: cytomegalovirus infection in inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; **42**: 127-129 [PMID: 26040530 DOI: 10.1111/apt.13234]

34 **Kou T**, Nakase H, Tamaki H, Kudo T, Nishio A, Chiba T. Cytomegalovirus infection in patients with ulcerative colitis diagnosed by quantitative real-time PCR analysis. *Dig Dis Sci* 2006; **51**: 1052-1055 [PMID: 16865568 DOI: 10.1007/s10620-006-8006-y]

35 **Kleer CG**, Appelman HD. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. *Am J Surg Pathol* 1998; **22**: 983-989 [PMID: 9706978]

36 **Kim B**, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. *Am J Gastroenterol* 1999; **94**: 3258-3262 [PMID: 10566726 DOI: 10.1111/j.1572-0241.1999.01533.x]

37 **Joo M**, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. *Am J Surg Pathol* 2010; **34**: 689-696 [PMID: 20410806 DOI: 10.1097/PAS.0b013e3181db84cd]

38 **Shah SN**, Amarapurkar AD, Shrinivas N, Rathi PM. Atypical histological features of ulcerative colitis. *Trop Gastroenterol* 2011; **32**: 107-111 [PMID: 21922873]

39 **DeRoche TC**, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)* 2014; **2**: 178-192 [PMID: 24942757 DOI: 10.1093/gastro/gou031]

40 **Park SH**, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. *Can J Gastroenterol Hepatol* 2014; **28**: 125-130 [PMID: 24619632]

41 **McCurdy JD**, Jones A, Enders FT, Killian JM, Loftus EV, Smyrk TC, Bruining DH. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2015; **13**: 131-17; quiz e7 [PMID: 24993369 DOI: 10.1016/j.cgh.2014.05.026]

42 **Omiya M**, Matsushita M, Tanaka T, Kawamata S, Okazaki K. The absence of large ulcer predicts latent cytomegalovirus infection in ulcerative colitis with positive mucosal viral assay. *Intern Med* 2010; **49**: 2277-2282 [PMID: 21048360]

43 **Boom R**, Sol C, Weel J, Lettinga K, Gerrits Y, van Breda A, Wertheim-Van Dillen P. Detection and quantitation of human cytomegalovirus DNA in faeces. *J Virol Methods* 2000; **84**: 1-14 [PMID: 10644082]

44 **Ganzenmueller T**, Kluba J, Becker JU, Bachmann O, Heim A. Detection of cytomegalovirus (CMV) by real-time PCR in fecal samples for the non-invasive diagnosis of CMV intestinal disease. *J Clin Virol* 2014; **61**: 517-522 [PMID: 25453330 DOI: 10.1016/j.jcv.2014.10.009]

45 **Herfarth HH**, Long MD, Rubinas TC, Sandridge M, Miller MB. Evaluation of a non-invasive method to detect cytomegalovirus (CMV)-DNA in stool samples of patients with inflammatory bowel disease (IBD): a pilot study. *Dig Dis Sci* 2010; **55**: 1053-1058 [PMID: 20165976 DOI: 10.1007/s10620-010-1146-0]

46 **Sun YQ**, Xu LP, Han TT, Zhang XH, Wang Y, Han W, Wang FR, Wang JZ, Chen H, Chen YH, Yan CH, Chen Y, Liu KY, Huang XJ. Detection of human cytomegalovirus (CMV) DNA in feces has limited value in predicting CMV enteritis in patients with intestinal graft-versus-host disease after allogeneic stem cell transplantation. *Transpl Infect Dis* 2015; **17**: 655-661 [PMID: 26275161 DOI: 10.1111/tid.12420]

47 **Bitton A**, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. *Am J Gastroenterol* 2012; **107**: 179-94; author reply 195 [PMID: 22108451 DOI: 10.1038/ajg.2011.386]

48 **Shukla T**, Singh S, Loftus EV, Bruining DH, McCurdy JD. Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis. *Inflamm Bowel Dis* 2015; **21**: 2718-2725 [PMID: 26197450 DOI: 10.1097/MIB.0000000000000489]

49 **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013]

50 **Pillet S**, Pozzetto B, Jarlot C, Paul S, Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. *Dig Liver Dis* 2012; **44**: 541-548 [PMID: 22538204 DOI: 10.1016/j.dld.2012.03.018]

51 **Vega R**, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, Cabré E, Ojanguren I, Gassull MA. Cytomegalovirus infection in patients with inflammatory bowel disease. *Am J Gastroenterol* 1999; **94**: 1053-1056 [PMID: 10201482 DOI: 10.1111/j.1572-0241.1999.01013.x]

52 **Cottone M**, Pietrosi G, Martorana G, Casà A, Pecoraro G, Oliva L, Orlando A, Rosselli M, Rizzo A, Pagliaro L. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. *Am J Gastroenterol* 2001; **96**: 773-775 [PMID: 11280549 DOI: 10.1111/j.1572-0241.2001.03620.x]

53 **Papadakis KA**, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. *Am J Gastroenterol* 2001; **96**: 2137-2142 [PMID: 11467645 DOI: 10.1111/j.1572-0241.2001.03949.x]

54 **Wada Y**, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, Yorioka M, Tsuda S, Yao T, Yao S, Haraoka S, Iwashita A. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. *Dis Colon Rectum* 2003; **46**: S59-S65 [PMID: 14530660 DOI: 10.1097/01.DCR.0000087486.21981.C6]

55 **Criscuoli V**, Casà A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. *Dig Liver Dis* 2004; **36**: 818-820 [PMID: 15646428 DOI: 10.1016/j.dld.2004.05.013]

56 **Kambham N**, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. *Am J Surg Pathol* 2004; **28**: 365-373 [PMID: 15104299]

57 **Kishore J**, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. *J Med Microbiol* 2004; **53**: 1155-1160 [PMID: 15496396]

58 **Alain S**, Ducancelle A, Le Pors MJ, Mazeron MC, de Saussure P, Bouhnik Y, Lavergne A. Cytomegalovirus infection in patients with active inflammatory bowel disease. *J Clin Virol* 2005; **33**: 180-182 [PMID: 15911437 DOI: 10.1016/j.jcv.2005.01.001]

59 **Maconi G**, Colombo E, Zerbi P, Sampietro GM, Fociani P, Bosani M, Cassinotti A, Casini V, Russo A, Ardizzone S, Porta M, Bianchi Porro G. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. *Dig Liver Dis* 2005; **37**: 418-423 [PMID: 15893280 DOI: 10.1016/j.dld.2005.01.011]

60 **Kojima T**, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. *Scand J Gastroenterol* 2006; **41**: 706-711 [PMID: 16716970 DOI: 10.1080/00365520500408584]

61 **Lavagna A**, Bergallo M, Daperno M, Sostegni R, Ravarino N, Crocellà L, Ramella A, Rocca R, Torchio B, Cavallo R, Pera A. The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. *Dig Liver Dis* 2006; **38**: 887-893 [PMID: 16931197 DOI: 10.1016/j.dld.2006.07.011]

62 **Minami M**, Ohta M, Ohkura T, Ando T, Ohmiya N, Niwa Y, Goto H. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. *World J Gastroenterol* 2007; **13**: 754-760 [PMID: 17278199 DOI: 10.3748/wjg.v13.i5.754]

63 **Matsuoka K**, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. *Am J Gastroenterol* 2007; **102**: 331-337 [PMID: 17156136 DOI: 10.1111/j.1572-0241.2006.00989.x]

64 **Domènech E**, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. *Inflamm Bowel Dis* 2008; **14**: 1373-1379 [PMID: 18452205 DOI: 10.1002/ibd.20498]

65 **Maher MM**, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. *Dig Dis Sci* 2009; **54**: 2456-2462 [PMID: 19093204 DOI: 10.1007/s10620-008-0639-6]

66 **Suzuki H**, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yamamoto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. *World J Gastroenterol* 2010; **16**: 1245-1251 [PMID: 20222169 DOI: 10.3748/wjg.v16.i10.1245]

67 **Criscuoli V**, Rizzuto MR, Montalbano L, Gallo E, Cottone M. Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. *World J Gastroenterol* 2011; **17**: 633-638 [PMID: 21350712 DOI: 10.3748/wjg.v17.i5.633]

68 **Kim YS**, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS, Yang SK, Kim WH. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. *J Clin Gastroenterol* 2012; **46**: 51-56 [PMID: 21552140 DOI: 10.1097/MCG.0b013e3182160c9c]

69 **Yoshino T**, Nakase H, Matsuura M. Letter: Mucosal PCR for cytomegalovirus in refractory ulcerative colitis. *Aliment Pharmacol Ther* 2012; **36**: 811-82; author reply 812 [PMID: 22984956 DOI: 10.1111/apt.12009]

70 **Fukuchi T**, Nakase H, Matsuura M, Yoshino T, Toyonaga T, Ohmori K, Ubukata S, Ueda A, Eguchi T, Yamashita H, Ito D, Ashida K. Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. *J Crohns Colitis* 2013; **7**: 803-811 [PMID: 23352104 DOI: 10.1016/j.crohns.2012.12.003]

71 **Iida T**, Ikeya K, Watanabe F, Abe J, Maruyama Y, Ohata A, Teruyuki S, Sugimoto K, Hanai H. Looking for endoscopic features of cytomegalovirus colitis: a study of 187 patients with active ulcerative colitis, positive and negative for cytomegalovirus. *Inflamm Bowel Dis* 2013; **19**: 1156-1163 [PMID: 23619714 DOI: 10.1097/MIB.0b013e31828075ce]

72 **Kopylov U**, Sasson G, Geyshis B, Oikawa MT, Barshack I, Eliakim R, Ben-Horin S. Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. *World J Gastrointest Pathophysiol* 2013; **4**: 18-23 [PMID: 23596551 DOI: 10.4291/wjgp.v4.i1.18]

73 **Delvincourt M**, Lopez A, Pillet S, Bourrier A, Seksik P, Cosnes J, Carrat F, Gozlan J, Beaugerie L, Roblin X, Peyrin-Biroulet L, Sokol H. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. *Aliment Pharmacol Ther* 2014; **39**: 712-720 [PMID: 24506221 DOI: 10.1111/apt.12650]

74 **do Carmo AM**, Santos FM, Ortiz-Agostinho CL, Nishitokukado I, Frota CS, Gomes FU, Leite AZ, Pannuti CS, Boas LS, Teixeira MG, Sipahi AM. Cytomegalovirus infection in inflammatory bowel disease is not associated with worsening of intestinal inflammatory activity. *PLoS One* 2014; **9**: e111574 [PMID: 25387236 DOI: 10.1371/journal.pone.0111574]

75 **Inokuchi T**, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. *World J Gastroenterol* 2014; **20**: 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509]

76 **Kim YS**, Kim YH, Kim JS, Jeong SY, Park SJ, Cheon JH, Ye BD, Jung SA, Park YS, Choi CH, Kim KO, Jang BI, Han DS, Yang SK, Kim WH. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. *Gut Liver* 2014; **8**: 643-647 [PMID: 25368753 DOI: 10.5009/gnl13427]

77 **Kim JW**, Boo SJ, Ye BD, Kim CL, Yang SK, Kim J, Kim SA, Park SH, Park SK, Yang DH, Jung KW, Kim KJ, Byeon JS, Myung SJ, Kim JH. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. *J Crohns Colitis* 2014; **8**: 693-701 [PMID: 24405983 DOI: 10.1016/j.crohns.2013.12.014]

78 **Maconi G**, Lombardini M, Furfaro F, Bezzio C, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. *Eur J Gastroenterol Hepatol* 2014; **26**: 1146-1151 [PMID: 25089547 DOI: 10.1097/MEG.0000000000000175]

79 **Matsumoto S**, Yoshida Y. What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis? *Eur J Gastroenterol Hepatol* 2014; **26**: 282-287 [PMID: 24374839 DOI: 10.1097/MEG.0000000000000028]

80 **Olaisen M**, Rydning A, Martinsen TC, Nordrum IS, Mjønes P, Fossmark R. Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. *Scand J Gastroenterol* 2014; **49**: 845-852 [PMID: 24947587 DOI: 10.3109/00365521.2014.929172]

81 **Yamada S**, Yoshino T, Matsuura M, Minami N, Toyonaga T, Honzawa Y, Tsuji Y, Nakase H. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. *BMC Gastroenterol* 2014; **14**: 80 [PMID: 24758588 DOI: 10.1186/1471-230X-14-80]

82 **Chun J**, Lee C, Kwon JE, Hwang SW, Kim SG, Kim JS, Jung HC, Im JP. Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. *Intest Res* 2015; **13**: 50-59 [PMID: 25691843 DOI: 10.5217/ir.2015.13.1.50]

83 **Jones A**, McCurdy JD, Loftus EV, Bruining DH, Enders FT, Killian JM, Smyrk TC. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. *Clin Gastroenterol Hepatol* 2015; **13**: 949-955 [PMID: 25283582 DOI: 10.1016/j.cgh.2014.09.042]

84 **Gauss A**, Rosenstiel S, Schnitzler P, Hinz U, Rehlen T, Kadmon M, Ehehalt R, Stremmel W, Zawierucha A. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: a 10-year tertiary referral center experience. *Eur J Gastroenterol Hepatol* 2015; **27**: 712-720 [PMID: 25919654 DOI: 10.1097/MEG.0000000000000361]

85 . Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol 2015; e000021 [DOI: 10.1136/bmjgast-2014-000021]

86 **de Saussure P**, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. *Aliment Pharmacol Ther* 2004; **20**: 1323-1327 [PMID: 15606394 DOI: 10.1111/j.1365-2036.2004.02273.x]

87 **Chiba M**, Abe T, Tsuda S, Ono I. Cytomegalovirus infection associated with onset of ulcerative colitis. *BMC Res Notes* 2013; **6**: 40 [PMID: 23375026 DOI: 10.1186/1756-0500-6-40]

88 **Martin SI**, Sepehr A, Fishman JA. Primary infection with cytomegalovirus in ulcerative colitis. *Dig Dis Sci* 2006; **51**: 2184-2187 [PMID: 17120145 DOI: 10.1007/s10620-006-9474-9]

89 **Streetz KL**, Buhr T, Wedemeyer H, Bleck J, Schedel I, Manns MP, Göke MN. Acute CMV-colitis in a patient with a history of ulcerative colitis. *Scand J Gastroenterol* 2003; **38**: 119-122 [PMID: 12608474]

90 **Hamlin PJ**, Shah MN, Scott N, Wyatt JI, Howdle PD. Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature. *Postgrad Med J* 2004; **80**: 233-235 [PMID: 15082847]

91 **Kornbluth A**, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010; **105**: 501-23; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727]

92 **Widmann T**, Sester U, Gärtner BC, Schubert J, Pfreundschuh M, Köhler H, Sester M. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. *PLoS One* 2008; **3**: e3634 [PMID: 18982061 DOI: 10.1371/journal.pone.0003634]

93 **Van Damme E**, Sauviller S, Lau B, Kesteleyn B, Griffiths P, Burroughs A, Emery V, Sinclair J, Van Loock M. Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. *J Gen Virol* 2015; **96**: 131-143 [PMID: 25312585 DOI: 10.1099/vir.0.069872-0]

94 **Inoue-Toyoda M**, Kato K, Nagata K, Yoshikawa H. Glucocorticoids facilitate the transcription from the human cytomegalovirus major immediate early promoter in glucocorticoid receptor- and nuclear factor-I-like protein-dependent manner. *Biochem Biophys Res Commun* 2015; **458**: 180-185 [PMID: 25640841 DOI: 10.1016/j.bbrc.2015.01.091]

95 **D'Ovidio V**, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, Martino P, Caprilli R. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. *J Clin Virol* 2008; **43**: 180-183 [PMID: 18614396 DOI: 10.1016/j.jcv.2008.06.002]

96 **Criscuoli V**, Mocciaro F, Orlando A, Rizzuto MR, Renda MC, Cottone M. Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis. *Inflamm Bowel Dis* 2009; **15**: 810-811 [PMID: 18839422 DOI: 10.1002/ibd.20742]

97 **Nakase H**, Chiba T. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. *Inflamm Bowel Dis* 2010; **16**: 550-551 [PMID: 19637380 DOI: 10.1002/ibd.21047]

98 **Nakase H**, Yamamoto S, Matsuura M, Honzawa Y, Chiba T. Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. *Aliment Pharmacol Ther* 2010; **32**: 510-511 [PMID: 20636704 DOI: 10.1111/j.1365-2036.2010.04372.x]

99 **Lavagna A**, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, Crocellà L, Molinaro G, Rocca R, Cavallo R, Pera A. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. *Inflamm Bowel Dis* 2007; **13**: 896-902 [PMID: 17345605 DOI: 10.1002/ibd.20131]

100 **Pillet S**, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. *Inflamm Bowel Dis* 2015; **21**: 1580-1586 [PMID: 25933392 DOI: 10.1097/MIB.0000000000000412]

101 **Roblin X**, Del Tedesco E. Tacrolimus in the management of hospitalized patients with steroid-refractory ulcerative colitis: don't forget cytomegalovirus! *Inflamm Bowel Dis* 2013; **19**: E67-E68 [PMID: 23314247 DOI: 10.1097/MIB.0b013e318281013f]

102 **Barahona-Garrido J**, Martínez-Benítez B, Espinosa-Cárdenas E, Sarti HM, Gutiérrez-Manjarrez JI, Aguirre-Gutiérrez R, Tellez-Avila FI, Coss-Adame E, García-Juárez I, Yamamoto-Furusho JK. Cytomegalovirus infection in patients who required colectomy for toxic megacolon or severe steroid-refractory ulcerative colitis. *Dig Dis Sci* 2010; **55**: 867-868 [PMID: 20094780 DOI: 10.1007/s10620-009-1109-5]

103 **Wu XW**, Wu L, Ji HZ, Wang FY. Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis. *Dig Dis Sci* 2015; **60**: 3203-3208 [PMID: 26031424 DOI: 10.1007/s10620-015-3733-6]

104 **Powell RD**, Warner NE, Levine RS, Kirsner JB. Cytomegalic inclusion disease and ulcerative colitis. Report of a case in a young adult. *Am J Med* 1961; **30**: 334-340 [PMID: 13737621]

105 **Uchino M**, Matsuoka H, Bando T, Hirata A, Sasaki H, Hirose K, Takesue Y, Nakamura S, Tomita N, Ikeuchi H. Clinical features and treatment of ulcerative colitis-related severe gastroduodenitis and enteritis with massive bleeding after colectomy. *Int J Colorectal Dis* 2014; **29**: 239-245 [PMID: 24105365 DOI: 10.1007/s00384-013-1779-5]

106 **Hantz S**, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. *J Antimicrob Chemother* 2010; **65**: 2628-2640 [PMID: 20961907 DOI: 10.1093/jac/dkq368]

107 **Sands BE**, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. *Gastroenterology* 2008; **135**: 400-409 [PMID: 18602921 DOI: 10.1053/j.gastro.2008.04.023]

108 **Yoshino T**, Nakase H, Matsuura M, Matsumura K, Honzawa Y, Fukuchi T, Watanabe K, Murano M, Tsujikawa T, Fukunaga K, Matsumoto T, Chiba T. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants. *Digestion* 2011; **84**: 3-9 [PMID: 21311190 DOI: 10.1159/000321911]

109 **Sager K**, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; **41**: 725-733 [PMID: 25684400 DOI: 10.1111/apt.13124]

**P-Reviewer:** Annese V, Caviglia RD, Goenka MK, Maltz C, Miheller P

**S-Editor:** Yu J **L-Editor:** **E-Editor:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Markers** | **Biological specimens** | **Technique(s)** | **Delay to result** | **Advantages** | **Disadvantages** | **Illustration** |
| IgG antibodies to CMV | Peripheral blood |  ELISA | Few hours | Marker of previousinfection with CMVPossible dating of primary infection by testing IgG avidity | - | http://www.mobitec.com/cms/bilder/products/invitro_diagn/CMV2.jpg |
| IgM antibodies to CMV | Peripheral blood | ELISA | Few hours | Marker of recent infection with CMV | False positive resultsPossible persistence for several weeks or months |
| Classical cell culture | Peripheral blood, saliva, urines, tissues, fluids | Detection of cytopathic effect in tissue culture | Days or weeks | Isolation of infectious viruses and of clinical strains | FastidiousPoorly sensitiveLong lasting |  |
| ‘Rapid’ cell culture | Urines | Centrifugation of clinical specimen on tissue culture and detection of viral proteins expressed at early stages of infection | 2 d | Screening test for CMV detection in urineFaster than classical cell culture | FastidiousNo strain isolation |  |
| Histological examinationafter HE staining | Tissue | Detection of infected cells with characteristic aspects (*i.e.* “owl’s eye”, intracellular inclusion bodies) in tissue specimens | Few days | No specific reagents required | FastidiousPoorly sensitiveNeed trained pathologist |  |
| Detection of antigens | Peripheral blood | pp65 antigenemia (detection of viral inclusions in polymorphonuclear cells) | 24 h | Presence of active blood infection (viremia)Quantitation of positive cells | Not automatedLow sensitivity compared to NAAT |  |
| Detection of antigens | Tissue | IHC | Few days | Presence of active tissue infectionQuantitation of positive cells | Not automatedLow sensitivity compared to NAAT | 282507.fig.001b |
| Detection of viral nucleic acids in infected cells | Tissue | *In situ* hybridization  | Few days | Presence of active tissue infectionQuantitation of positive cells | Not automatedLow sensitivity compared to NAAT |  |
| Molecular amplification of nucleic acids | All specimens including tissues | Quantitative PCR or other molecular techniques | Few hours | Possible automationPossible quantitation (measure of viral load) | Need a laboratory trained in molecular biology |  |

**Figure 1 Techniques currently used for the detection of markers of cytomegalovirus infection.** Analyses highlighted in dark pink are very useful, those highlighted in light pink of little use, and those without color of no use, for the diagnosis of cytomegalovirus reactivation in inflammatory bowel diseases. ELISA: Enzyme-linked immunosorbent assay; IHC: Immunohistochemistry; CMV: Cytomegalovirus; HE staining: Hematoxylin and eosin staining; NAAT: Nucleic acid amplification test.



**Figure 2 Therapeutic algorithm for the intake of flare-ups of refractory ulcerative colitis in patients older than 30 years according to the quantification of cytomegalovirus density in colonic tissue.** 1Defined by steroid resistance or immunosuppressive treatment or anti-TNF drugs;2Defined by quantification of CMV DNA in intestinal tissue of 10 to 250 copies/mg of inflamed tissue or low-grade CMV density by IHC in biopsy specimens (4 inclusions or less);3Defined by quantification of CMV DNA in intestinal tissue of > 250 copies/mg of inflamed tissue or high-grade CMV density by IHC in biopsy specimens (more than 4 inclusions);4Defined by a need for hospitalization and a Lichtiger score > 10. TNF: Tumor necrosis factor; CMV: Cytomegalovirus.

**Table 1 Main studies recording the impact of cytomegalovirus on inflammatory bowel diseases course**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Studies by chronological order** | **Number of studied patients by type of IBD** | **Method used for CMV detection** | **Main results of the study** | **Impact of CMV** |
| Vega *et al*[51], 1999 | 7UC and 2 CD | Histology and IHC | Ganciclovir allowed clinical remission in 5/7 patients, with absence of CMV markers after antiviral therapy | Unfavorable |
| Cottone *et al*[52], 2001 | 55UC and 7 CD | Histology and IHCPCR in PBMC | Antiviral treatment (3 with ganciclovir and 2 with foscarnet) allowed clinical remission in 5/7 patients | Unfavorable |
| Papadakis *et al*[53], 2001 | 5 UC, 3 CD, 2 indeterminate colitis ; all medically refractory | Heterogeneous (serology, histology, IHC, ISH, PCR, cell culture) | Ganciclovir improved clinical outcome in 8/9 patients | Unfavorable |
| Wada *et al*[54], 2003 | 47 moderate to severe UC | pp65 antigenemia and IHC | Association of CMV infection with steroid resistance [13/16 (81.3%) *vs* 9/31 (29%), *P =* 0.001] and severe endoscopic score (*P <* 0.05); ganciclovir effective in 8/12 patients (66.7%) | Unfavorable |
| Criscuoli *et al*[55], 2004 | 38 UC and 4 CD with severe disease | pp65 antigenemia, qualitative PCR in leucocytes, histology and IHC | No clear association with steroid resistance, no need for antiviral therapy | None |
| Kambham *et al*[56], 2004 | 80 UC | IHC | CMV detected in 10 of 40 (25%) patients with refractory UC *vs* 1 of 40 (2.5%) patients with nonrefractory UC | Unfavorable |
| Kishore *et al*[57], 2004 | 61 UC and 2 CD | Serology (IgM), qualitative PCR in biopsy | CMV infection associated with poor outcome, with surgical treatment (4/10 *vs* 4/53, *P <* 0.05) and death (3/10 *vs* 0/53, *P <* 0.005) | Unfavorable |
| Alain *et al*[58], 2005 | 63 CD and 28 UC | Serology (IgM), viruria, pp65 antigenemia, detection of mRNA in blood, tissue cell culture of blood and tissue, histology and IHC | 8/14 patients with CMV infection experienced high dose steroid or azathioprine ; ganciclovir improved 4/4 treated patients | Unfavorable |
| Maconi *et al*[59], 2005 | 77 UC with colectomy | Histology and IHC | Trend for an association between CMV reactivation and corticoresistance (15/55, 27.3% *vs* 2/22, 9.1%, *P =* 0.123) | Unfavorable |
| Dimitroulia *et al*[12], 2006 | 58 UC and 27 CD | PCR in blood and IHC | No association with disease severity | None |
| Kojima *et al*[60], 2006 | 126 UC with colectomy | Histology and IHC | CMV markers in surgical specimens more frequently detected in patients with severe or refractory disease | Unfavorable |
| Lavagna *et al*[61], 2006 | 24 refractory UC leading to colectomy | IHC and PCR in tissue | No pouchitis in CMV positive patients (compared to 3/21 of CMV negative ones) | None |
| Kuwabara *et al*[13], 2007 | 34 UC and 16 CD | IHC | CMV positive cell density associated with steroid resistance and colectomy rate | Unfavorable |
| Minami *et al*[62], 2007 | 23 severe UC | Heterogeneous (serology or histology or IHC or PCR in blood) | 18 out 23 patients receiving cyclosporine exhibited CMV infection; 15/18 (83.3%) CMV positive required colectomy; colectomy could be avoided in the 3 remaining patients by administration of ganciclovir | Unfavorable |
| Matsuoka *et al*[63], 2007 | 69 moderate to severe UC | pp65 antigenemia and qPCR in plasma, histology | Low peripheral viral load observed in 25/48 patients; none exhibited CMV markers in tissue. No impact on clinical outcome and spontaneous clearance of CMV markers in blood without ganciclovir | None |
| Yoshino *et al*[14], 2007 | 30 UC refractory to immunosuppressive therapies | qPCR in tissue | Clinical remission after ganciclovir alone in 4/12 treated, the remaining 8 required additional anti-inflammatory treatment | Unfavorable |
| Domènech *et al*[64], 2008 | 114 active UC | pp65 antigenemiatissue: histology, IHC and detection of pp67 mRNA | Steroid and cyclosporine treatment predisposes to CMV reactivation in colon (6/19); ganciclovir associated to remission in 3/6 patients; CMV markers detected in 2 surgical specimens | Unfavorable |
| Maher *et al*[65], 2009 | 49 UC and 23 CD with active disease | Serology, histology and IHC | CMV infection more frequent in steroid resistant patients (8/23, 34.8% *vs* 1/31, 3.2%) | Unfavorable |
| Kim *et al*[17], 2010 | 122 UC | IHC | CMv positive patients required hospitalization (OR: 4.9; 95%CI: 1.2-19.0) and were hospitalized ≥ 7 d (OR: 5.0; 95%CI: 1.6-21.3) | Unfavorable |
| Lévêque *et al*[16], 2010 | 33 CD and 20 UC | qPCR in tissue | CMV infection more frequent after corticoid or azathioprine therapy; no relation with disease severity; no need of antiviral therapy | None |
| Omiya *et al*[42], 2010 | 20 UC | PCR in tissue | Absence of large ulcer in case of CMV infection | None |
| Suzuki *et al*[66], 2010 | 73 UC | pp65 antigenemia | Irregular ulceration associated to 100% of CMV infection | Unfavorable |
| Criscuoli *et al*[67], 2011 | 28 UC with CMV reactivation | Histology, IHC and nested PCR in tissue | Persistence of CMV markers in colon after acute colitis flare-up despite remission | None |
| Nguyen *et al*[22], 2011 | 26 UC and 17 CD | Histology and IHC | Higher colectomy rate in patients exhibiting high grade infection; decreased colectomy rate with ganciclovir use | Unfavorable |
| Roblin *et al*[10], 2011 | 42 moderate to severe UC | qPCR in tissue | The tissue CMV DNA load is predictive of resistance to immunosuppressive therapy ; ganciclovir treatment cleared CMV DNA in tissue and improved outcome in 7/8 patients | Unfavorable |
| Al-Zafiri *et al*[20], 2012 | 13 CD and 18 UC with CMV reactivation | IHC | Colectomy rate higher (9/31, 29%) in CMV positive than in CMV negative (65/581, 11.2%) IBD patients | Unfavorable |
| Kim *et al*[68], 2012 | 72 moderate to severe UC treated with IV steroids | PCR in tissue | Association of CMV infection with steroid resistance; clinical improvement after ganciclovir (11/14) | Unfavorable |
| Yoshino *et al*[69], 2012 | 17 UC refractory to tacrolimus | qPCR in tissue | Colectomy-free time lower in CMV positive patients than in CMV-negative ones (35.7% at 17.7 mo *vs* 88.9% at 45.9 mo respectively, log-rank test *P <* 0.005) | Unfavorable |
| Fukuchi *et al*[70], 2013 | 51 active UC | IHC or qPCR in tissue | CMV DNA became negative after GMAA in patients with clinical remission | Unfavorable |
| IIda *et al*[71], 2013 | 187 active UC | pp65 antigenemia | CMV infection more frequent in steroid refractory patients (27/82, 32.9% *vs* 6/105, 5.7%) | Unfavorable |
| Kopylov *et al*[72], 2013 | 13 UC with CMV reactivation | IHC | The disease was more severe in the 7 patients requiring ganciclovir therapy, including one death and three colectomies | Unfavorable |
| Delvincourt *et al*[73], 2014 | 26 UC and 110 IBD hospitalized | qPCR in blood or tissue | No alteration of the course of IBD flare | None |
| Do Carmo *et al*[74], 2014 | 249 CD+151 UC | Qualitative PCR in stools | CMV infection is rare (only 9 patients) and is not associated with IBD disease activity | None |
| Inokuchi *et al*[75], 2014 | 118 UC | pp65 antigenemia | Delay to clinical remission higher in CMV positive patients (21 d *vs* 16 d, *P <* 0.01); ganciclovir decreased the rate of colectomy in multivariate analysis | Unfavorable |
| Kim *et al*[76], 2014 | 72 moderate to severe UC | Heterogeneous (serology or histology or IHC or PCR) | Cumulative colectomy (log rank, *P =* 0.025) and disease flare-up rates (log-rank, *P =* 0.048) higher in CMV positive patients | Unfavorable |
| Kim *et al*[77], 2014 | 229 moderate to severe UC | IHC and pp65 antigenemia | Association between positive pp65 antigenemia and rate of colectomy (13/39, 33.3% *vs* 5/44, 11.4%, *P <* 0.05) | Unfavorable |
| Maconi *et al*[78], 2014 | 30 UC and 8 CD with active colitis and CMV infection | Histology/IHC | Antiviral therapy associated with a higher clinical remission rate at 12 mo (77.8% *vs* 45%, *P <* 0.05, and 77.8% *vs* 19.4%, *P <* 0.05) in UC patients and patients with steroid-dependent/refractory disease, respectively | Unfavorable |
| Matsumoto *et al*[79], 2014 | 222 UC | Antigenemia, histology, PCR | CMV infection as a risk factor for hospitalization because of UC aggravation (OR: 8.2, 95%CI: 1.91-35.33; *P <* 0.005) | Unfavorable |
| Olaisen *et al*[80], 2014 | 77 patients undergoing colectomy | IHC | CMV positive patients received higher doses of corticoids and were at higher risk of post-operative complications | Unfavorable |
| Yamada *et al*[81], 2014 | 33 refractory UC | qPCR in tissue | Induction remission rate by infliximab lower (54.5%) in CMV-positive patients than in CMV-negative ones (81.8%) although not statistically significant | Unfavorable |
| Chun *et al*[82], 2015 | 43 moderate to severe UC | pp65 antigenemia | Positive antigenemia associated with steroid refractoriness (11/12, 91.7% *vs* 12/31, 38.7%, *P <* 0.005); ganciclovir improved outcome: colectomy in 2/8 (25%) *vs* 2/4 (50%) | Unfavorable |
| Ciccocioppo *et al*[32], 2015 | 24 UC and 16 CD | qPCR in tissue | In refractory patients, more frequent CMV infection and higher viral load; efficacy of ganciclovir in all refractory patients | Unfavorable |
| Jones *et al*[83], 2015 | 1111 IBD patients | Histology, IHC, ISH | Antiviral therapy improved surgery-free survival outcome | Unfavorable |
| Gauss *et al*[84], 2015 | 166 UC and 131 CD | IHC and PCR in tissue | CMV reactivation associated to longer hospital stay (*P <* 0.001) | Unfavorable |
| McCurdy *et al*[41], 2015 | 45 UC, 21 CD and 2 indeterminate IBD colitis | Histology, ISH, IHC | CMV reactivation associated to medically refractory disease (OR =3.69, *P <* 0.001) and endoscopic ulcers (OR = 2.95, *P <* 0.001) | Unfavorable |
| Minami *et al*[85], 2015 | 29 severe UC treated either with tacrolimus or infliximab | qPCR in tissue | Colectomy rate higher in patients with CMV infection (5/6, 83.3% *vs* 8/23, 34.8%, *P <* 0.05) | Unfavorable |

GMAA: Granulocyte/monocyte adsorptive apheresis; IHC: Immunohistochemistry; ISH: *In situ* hybridization; NAAT: Nucleic acid amplification test; PBMC: Peripheral blood monocular cells; PCR: Polymerase chain reaction; qPCR: Quantitative real-time PCR; IBD: Inflammatory bowel diseases; CD: Crohn’s disease; UC: Ulcerative colitis.